Jesus G. Berdeja, MD, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.
Jesus G. Berdeja, MD, director, Myeloma Research, Sarah Cannon Research Institute, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.
BMS-986393 is a GPRC5D-directed CAR T-cell therapy. Interim results from the dose-escalation portion of a phase 1 trial (NCT04674813) examining the product were presented at the 2022 ASH Annual Meeting.
Patients on the trial were administered BMS-986393 across 5 dose levels, ranging from 50 x 106 CAR T cells to 450 x 106 CAR T cells, Berdeja explains. Among patients evaluable for efficacy (n = 19), BMS-986393 elicited an overall response rate of 89.5%, including a complete response rate of 47.4%, Berdeja says.
Regarding safety, any-grade neutropenia occurred in 66.7% of patients, Berdeja notes. Among non-hematologic treatment-emergent adverse effects, any-grade cytokine release syndrome (CRS) was reported in 63.6% of patients; however, only 6.1% of patients experienced grade 3/4 CRS, Berdeja concludes.